Literature DB >> 6814560

Maroteaux-Lamy syndrome, mild form--MPS vi b.

D E Paterson, G Harper, H J Weston, J Mattingley.   

Abstract

Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) form B is a rare disease occurring in siblings. It may present with radiological features like Perthes' disease or hypothyroidism. We report two such cases, and discuss the differential diagnosis of the spondylo-epiphyseal dysplasias. We stress the importance of final diagnosis by identifying a particular glycosaminoglycan excess in the urine and an enzyme deficiency in the fibroblasts aryl sulphatase B and N-acetylgalactosamine-4-sulphatase.

Entities:  

Mesh:

Year:  1982        PMID: 6814560     DOI: 10.1259/0007-1285-55-659-805

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

1.  Spondyloepiphyseal dysplasias and bilateral legg-calvé-perthes disease: diagnostic considerations for mucopolysaccharidoses.

Authors:  Nancy J Mendelsohn; Timothy Wood; Rebecca A Olson; Renee Temme; Susan Hale; Haoyue Zhang; Lisa Read; Klane K White
Journal:  JIMD Rep       Date:  2013-05-09

2.  Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.

Authors:  A C Crawley; G Yogalingam; V J Muller; J J Hopwood
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

Review 3.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

Review 4.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

Review 5.  Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literature.

Authors:  Agnieszka Jurecka; Ekaterina Zakharova; Vera Malinova; Elena Voskoboeva; Anna Tylki-Szymańska
Journal:  Clin Rheumatol       Date:  2013-11-13       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.